Jikei Nateglinide and Arbs for Vascular Intervention Study

Authors
Category Primary study
JournalUMIN Clinical Trials Registry
Year 2008
INTERVENTION: Nateglinide 30 to 90mg per times and Valsartan 80mg Nateglinide 30 to 90mg per times and Telmisartan 40mg CONDITION: type 2 diabetes mellitus PRIMARY OUTCOME: Change in cartoid plaque volume after; 24 weeks using 3‐Dimensional Ultrasound INCLUSION CRITERIA: Type 2 diabetic patients with hypertension gave written informed consent to participate in the study,and treated with Nateglinide and ARB.
Epistemonikos ID: ac60083f7f638581900a0293e2cdc00d687272a2
First added on: Aug 21, 2024